Clinical trial · Interventional
A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application
A New Efficient EBV AssociatedTechnologies of T Cells in Treating Malignant Tumors and Clinical Application
NCT02980315CI-TRIAL-00024976unknownPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the safety of the designed LMP1-CAR -T cells and determine whether the CAR-T cells are effective in the treatment of EBV associated malignant tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nasopharyngeal Neoplasms | Nasopharyngeal Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CAR-T cells | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- CAR-T cells
- description
- the group treat with CAR-T cells
- interventionNames
- Other: CAR-T cells
- type
- NO_INTERVENTION
- label
- placebo
- description
- the group treat with CAR-T cells
Primary outcomes (1)
- measure
- all cause mortality
- timeFrame
- one year
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Clinical diagnosis of nasopharyngeal carcinoma Exclusion Criteria: * •pregnant woman * severe autoimmune diseases * serious infection
References
Publications (0)
Data not yet available
No reference posted for this study.